Literature DB >> 24648300

M30 does not predict the severity of hepatosteatosis, whereas adiponectin level declined with increase of ALT and the severity of hepatic steatosis.

Sedat Caner1, Akif Altınbaş, Müyesser Saykı, Fatih Büyükcam, Barış Yılmaz, Erman Çakal, Şahin Çoban, Tuncay Delibaşı.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is an emerging problem all over the world. Because NAFLD and polycystic ovary syndrome (PCOS) are both closely related with insulin resistance, it would be necessary to determine the rate of presence of NAFLD in PCOS patients. So, this study aimed to investigate the utility of M30 in PCOS patients for the diagnosis of hepatic injury.
METHODS: Eighty patients with PCOS were included in the study. Ultrasonographic examination for the presence of hepatic steatosis, M30 serum level for determining the severity of ongoing apoptotic cell death in liver, and BARD index for defining the hepatic injury were performed during the study. 25-OH vitamin D and adiponectin level in sera were studied using ELISA (Enzyme-Linked ImmunoSorbent Assay).
RESULTS: M30 and vitamin D levels did not change significantly with the severity of hepatic steatosis. On the other hand, M30 levels showed a positive correlation with ALT and AST levels, and M30 level suddenly increased with the presence of hepatic steatosis from 159.7 to 170 U/l, however stabilized with the increasing severity of hepatic setatosis. Adiponectin levels decreased with the increasing severity of hepatic steatosis and significantly varied between ALT greater than 40 U/l and less than 40 U/l.
CONCLUSIONS: M30 level in serum increased with the appearance of hepatic steatosis and had a positive correlation with a noninvasive hepatic injury test, BARD (BMI, aspartate aminotransferase [AST]/alanine aminotransferase [ALT] ratio [AAR], diabetes mellitus [DM]) index. Adiponectin level decreased with the increasing ALT level and severity of hepatic steatosis.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  M30; adiponectin; polycystic ovary syndrome; transaminases; vitamin D

Mesh:

Substances:

Year:  2014        PMID: 24648300      PMCID: PMC6807500          DOI: 10.1002/jcla.21697

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  25 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  The interaction of hepatic lipid and glucose metabolism in liver diseases.

Authors:  Lars P Bechmann; Rebekka A Hannivoort; Guido Gerken; Gökhan S Hotamisligil; Michael Trauner; Ali Canbay
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

3.  Vitamin D ameliorates stress ligand expression elicited by free fatty acids in the hepatic stellate cell line LX-2.

Authors:  Seyda Seydel; Anja Beilfuss; Alişan Kahraman; Kıymet Aksoy; Guido Gerken; Hikmet Akkiz; Ali Canbay
Journal:  Turk J Gastroenterol       Date:  2011-08       Impact factor: 1.852

4.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.

Authors:  Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver
Journal:  J Clin Endocrinol Metab       Date:  2011-06-06       Impact factor: 5.958

5.  Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.

Authors:  Lars P Bechmann; Peri Kocabayoglu; Jan-Peter Sowa; Svenja Sydor; Jan Best; Martin Schlattjan; Anja Beilfuss; Johannes Schmitt; Rebekka A Hannivoort; Alpaslan Kilicarslan; Christian Rust; Frieder Berr; Oliver Tschopp; Guido Gerken; Scott L Friedman; Andreas Geier; Ali Canbay
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

6.  Dysregulated Krüppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma.

Authors:  Qi Li; Yong Gao; Zhiliang Jia; Lopa Mishra; Kun Guo; Zhiwei Li; Xiangdong Le; Daoyan Wei; Suyun Huang; Keping Xie
Journal:  Gastroenterology       Date:  2012-06-04       Impact factor: 22.682

Review 7.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Héctor F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  Fertil Steril       Date:  2008-10-23       Impact factor: 7.329

8.  Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome.

Authors:  Enrico Carmina; Micheline C Chu; Carlos Moran; Drew Tortoriello; Prati Vardhana; Gilberto Tena; Raymundo Preciado; Rogerio Lobo
Journal:  Fertil Steril       Date:  2007-06-11       Impact factor: 7.329

9.  Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C.

Authors:  Inga Wedemeyer; Lars P Bechmann; Margarethe Odenthal; Christoph Jochum; Guido Marquitan; Uta Drebber; Guido Gerken; Robert K Gieseler; Hans P Dienes; Ali Canbay
Journal:  J Hepatol       Date:  2008-11-07       Impact factor: 25.083

10.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Amy G Shah; Alison Lydecker; Karen Murray; Brent N Tetri; Melissa J Contos; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2009-06-10       Impact factor: 11.382

View more
  1 in total

1.  The Role of M30 in Predicting the Severity of Liver Fibrosis and Inflammation in Chronic Hepatitis B Patients.

Authors:  Baris Yilmaz; Bora Aktas; Akif Altinbas; Zeynep Ginis; Gulfer Ozturk; Fuat Ekiz; Serta Kilincalp; Murat Deveci; Zahide Simsek; Sahin Coban; Omer Basar; Osman Yuksel
Journal:  Hepat Mon       Date:  2016-08-10       Impact factor: 0.660

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.